Formulation: A crystalline solid
Formal Name: 2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
Purity: ≥98%
Formula Markup: C25H29N9O3
Formula Weight: 503,6
Shelf life (days): 1460
CAS Number: 377727-87-2
Notes: Preladenant is an orally bioavailable antagonist of the adenosine A2A receptor (Kis = 1.1 and 2.5 nM for human and rat receptors, respectively).{40675} It is selective for A2A receptors over A1, A2B, and A3 receptors (Kis = >1,000, >1,700, and >1,000 nM, respectively) as well as a panel of 59 receptors, enzymes, and ion channels. Preladenant inhibits adenylate cyclase activity (Kbs = 1.3 and 0.7 nM for human and rat receptors, respectively) induced by the A2A receptor agonist CGS 21680 (Item No. 17126). It inhibits catalepsy induced by haloperidol (Item No. 12014) in rats by 77 and 70% after 1 and 4 hours, respectively, when administered at a dose of 1 mg/kg. Preladenant also increases the efficacy of L-DOPA (Item No. 13248) when used in combination with eltoprazine (Item No. 18428) in a 6-OHDA rat lesion model of Parkinson’s disease dyskinesia.{40676}
English
Deutsch
